



**HAL**  
open science

## **Influence of DNA repair gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy**

Augusto Nogueira, Raquel Catarino, Ana Coelho, António Araújo, Mónica Gomes, Rui Medeiros

### ► **To cite this version:**

Augusto Nogueira, Raquel Catarino, Ana Coelho, António Araújo, Mónica Gomes, et al.. Influence of DNA repair gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. *Cancer Chemotherapy and Pharmacology*, 2009, 66 (3), pp.501-506. 10.1007/s00280-009-1187-2 . hal-00552480

**HAL Id: hal-00552480**

**<https://hal.science/hal-00552480>**

Submitted on 6 Jan 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Influence of DNA repair *RAD51* gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy

Augusto Nogueira · Raquel Catarino · Ana Coelho ·  
António Araújo · Mónica Gomes · Rui Medeiros

Received: 13 September 2009 / Accepted: 11 November 2009 / Published online: 4 December 2009  
© Springer-Verlag 2009

## Abstract

**Purpose** Lung cancer continues to be the most frequent cancer with approximately one million people worldwide dying of this disease each year. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. The *RAD51* protein is the key protein for homologous recombination, an evolutionarily conserved mechanism for DNA damage repair and the generation of genetic diversity. We conducted this study in order to investigate the effect of the *RAD51 G135C* polymorphism in treatment response to combined platinum taxanes/gemcitabine first line chemotherapy in NSCLC patients.

**Methods** We analysed *RAD51 G135C* polymorphism in 243 NSCLC patients using PCR–RFLP methodology.

**Results** There were no statistically significant differences between the groups of NSCLC patients with the different genotypes regarding tumour stage ( $p = 0.232$ ). Our results indicate that the mean survival rates were statistically different according to the patient's genotypes. The group of

patients carrying the C allele presented a higher mean survival rate than the other patients (56.0 months vs. 41.7 months;  $p = 0.024$ ). Moreover, regarding smoking history, our results demonstrate that overall survival time differed significantly according to the patient's genotypes in smoker and ex-smoker individuals ( $p = 0.034$ ). No statistically significant differences were found in the genotype frequencies and overall survival rate among non-smoker NSCLC patients ( $p = 0.413$ ).

**Conclusions** This is the first study evaluating the effect of the *RAD51 G135C* polymorphism in NSCLC patient survival. Our results suggest that *RAD51* genotypes could be useful molecular markers for predicting the clinical outcome of NSCLC patients.

**Keywords** *RAD51* · Non-small cell lung cancer · DNA repair · Overall survival

## Introduction

Lung cancer remains a major worldwide health problem, being the most common form of cancer in the world, both in terms of incidence, 12.3% of all cancers, and mortality, representing 17.8% of the number of deaths caused by cancer [18]. In Europe, each year more than 150,000 new cases are diagnosed, but only 10% can be cured and enjoy long-term survival, mostly because of advanced stage detection. The incidence of lung cancer is higher in men and in older individuals. However, during the past decade, the incidence of this disease in females has increased, due to the change of smoking habits in women [1, 19]. While 90% of people with lung cancer have a smoking history, only 10–15% of chronic smokers develop lung cancer, suggesting factors in addition to smoking exposure are relevant

A. Nogueira · R. Catarino · A. Coelho · M. Gomes ·  
R. Medeiros (✉)  
Molecular Oncology Unit, Portuguese Institute of Oncology,  
Instituto Português de Oncologia, Laboratórios—Piso 4,  
R. Dr. Ant. Bernardino Almeida, 4200-072 Porto, Portugal  
e-mail: ruimedei@ipoporto.min-saude.pt

R. Catarino · R. Medeiros  
ICBAS, Abel Salazar Institute for the Biomedical Sciences,  
Porto, Portugal

A. Araújo  
Medical Oncology Department,  
Portuguese Institute of Oncology, Porto, Portugal

R. Medeiros  
Faculty of Health Sciences of Fernando Pessoa University,  
Porto, Portugal

in the aetiology of this disease [45]. Age, smoking exposure, impaired lung function and family history have been identified as independent risk factors for this disease [1].

There are two major groups of lung carcinomas: small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for approximately 80% of all lung cancers and includes epidermoid (squamous cell) carcinoma (which accounts for 25–40% of all lung cancers), adenocarcinoma, undifferentiated non-small cell lung cancer and large cell carcinoma [15].

Lung carcinogenesis is a multi-step process of progressive disorganization characterized by events over latent periods of time, resulting from exposure to environmental insults [4].

Maintenance of genetic stability requires the co-ordination of a network of pathways such as cell cycle checkpoint, DNA replication, DNA repair/recombination and programmed cell death. In response to DNA damage, cells arrest their cell cycle progression, thus providing time for repair, or activate programmed cell death—both responses preventing transmission of genetic instability [21, 22]. Double-strand breaks (DSBs) are considered the principal lethal DNA damage [2]. There are two distinct mechanisms in damage repair of mammalian cells, such as homologous recombination (HR) and non-homologous end joining (NHEJ) [8].

The human *RAD51* gene has a key role in the homologous recombination and DNA repair [33]. This gene is located at chromosome position 15q15.1 [38], a region that exhibits loss of heterozygosity in a large range of tumours, including lung, colorectal and breast cancers [43]. The protein (hRAD51) encoded by this gene is highly similar to *Escherichia coli* RecA and *Saccharomyces cerevisiae* *RAD51* [20] and has been suggested to play a role as a tumour suppressor gene [33]. Several studies have reported that mutations in genes involved in DNA repair and in the maintenance of genome integrity may be responsible for an increase of cancer risk [34].

Homologous recombination (HR) effects DNA repair through the interaction of free DNA ends with a homologous DNA sequence that is used as a template for the high-fidelity repair of the DSB. HR is thought to be particularly important in DNA repair occurring during cellular replication [34, 44, 46]. RAD51 is one of the key proteins for HR, and functions by forming nucleoprotein filaments on single-stranded DNA, mediating homologous pairing and strand exchange reactions between single- and double-strand DNA during repair [41].

A single nucleotide polymorphism (SNP) in the 5'-untranslated region (5'-UTR) of the human *RAD51* gene, resulting in a G–C substitution at nucleotide 135 of the non-coding exon 1 has been described and referred to as G135C polymorphism [24]. The genetic variants of G135C

polymorphism have been associated with breast [7] and gastric cancers [30].

Our purpose was to investigate the potential prognostic and predictive roles of *RAD51* G135C polymorphism in NSCLC patients treated with combined platinum taxanes/gemcitabine first line chemotherapy.

## Materials and methods

### Patients

We conducted a hospital-based study analysing 234 Caucasian individuals from the north region of Portugal with NSCLC, admitted in the Portuguese Institute of Oncology, Porto, Portugal, between 1999 and 2008, who underwent first line platinum and taxanes/gemcitabine-based chemotherapy regimens. Assessment of the tumour stage was based on the TNM system proposed by the American Joint Committee on Cancer (AJCC). The median age at diagnosis was 64 years with a mean age of 62.44 years (SD = 10.01). Patient clinical characteristics, obtained from medical records, are described in Table 1. Genomic DNA was extracted from blood samples by using QIAamp DNA Blood Mini Kit (QIAGEN). All samples were obtained with the informed consent of the participants prior to their inclusion in the study, according to the declaration of Helsinki.

**Table 1** Patient clinical characteristics

Characteristic	No. of patients (N = 246)	%
Age		
Median, 64.00	246	100
Mean, 62.44 ± 10.01		
Gender		
Female	52	21.1
Male	194	78.9
Tobacco		
Non-smoker	65	26.4
Smoker/ex-smoker	181	73.6
Histologic type		
NSCLC epidermoid	92	37.4
NSCLC non-epidermoid	151	61.4
Others	3	1.2
Stage		
I	14	5.7
II	17	6.9
III	125	50.8
IV	90	36.6


### PCR–RFPL assay for detection of *RAD51* G135C polymorphism

For detection of the *RAD51* G135C polymorphism, we used polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) according to a previously published protocol [24]. The PCR amplification was performed by using the following primers: forward (5' TGGG AACTGCAACTCATCTGG-3') and reverse (5' GCGC TCCTCTCTCCAGCAG-3'). Conditions for PCR were an initial denaturation at 95°C for 5 min, followed by 35 cycles at 94°C for 1 min, 53°C for 30 s (annealing temperature), 72°C for 1 min, and ending with 72°C for 10 min. The resulting 157-bp product was incubated at 37°C/12–16 h (overnight) with 1 U of the restriction enzyme *Mva*I (Fermentas, ER0551). The restriction fragments were then visualized by 4% (p/v) agarose gel electrophoresis, with ethidium bromide staining. Three types of band patterns were obtained: will type homozygote (G/G), two bands corresponding to 71 and 86 bp; heterozygote (C/G), three bands corresponding to 157, 86 and 71 bp; and polymorphic homozygote (C/C), only one band with 157 bp (Fig. 1).

### Statistical analysis

Analysis of data was performed using the computer software Statistical Package for Social Sciences (SPSS) for Windows (version 17.0). Differences in proportions were evaluated by the  $\chi^2$  test.

The probabilities of survival were calculated, and the means and life tables were computed using the product-limit estimate of Kaplan and Meier. The curves were analysed by the Breslow (generalized Wilcoxon) test, a statistical test for equality of survival distributions. A level of  $P < 0.05$  was considered statistically significant. Survival



**Fig. 1** Analysis of the *RAD51* G135C polymorphism genotypes: *M*, 50 bp ladder; *lanes* 1, 2, 3, 4, and 5 homozygote GG; *lanes* 6 heterozygote GC; and *lane* 7 polymorphic homozygote CC

duration was defined as the time between diagnosis and either death or time of the last clinical evaluation of the patient.

### Results

We analysed *RAD51* G135C polymorphism genotypes using the PCR–RFLP methodology. The genotype frequencies observed were 85.4% for GG homozygous genotype, 13.8% for CG heterozygous genotype and 0.8% for CC homozygous genotype. There were no statistically significant differences between the groups of NSCLC patients with the different genotypes regarding tumour stage ( $p = 0.232$ ) (Table 2).


Concerning the overall survival rates found using Kaplan–Meier methodology (Fig. 2), we observed that the mean survival rates were statistically different according to the patient's genotypes. The group of patients carrying the C allele presented a higher mean survival rate than the other patients (56.0 months vs. 41.7 months;  $p = 0.024$ ). Thus, individuals with CC/GC genotypes showed a higher overall survival, conferring a better prognosis for C allele carrier patients. Moreover, regarding smoking history, our results demonstrate that overall survival time differed significantly according to the patient's genotypes in smoker and ex-smoker individuals ( $p = 0.034$ ). Patients carrying C allele presented a higher survival rate, comparing with the other patients (56.4 months vs. 44.7 months,  $p = 0.034$ ) (Fig. 3a). No statistically significant differences were found in the genotype frequencies and overall survival rate among non-smoker NSCLC patients ( $p = 0.413$ ) (Fig. 3b).

### Discussion


Lung cancer is one of the most common causes of cancer-related death. Non-small cell lung cancer accounts for 75–85% of all histologic types of lung cancer. Despite

**Table 2** Genotype frequencies of polymorphism in *RAD51* gene in NSCLC patients according tumour stage (Pearson  $\chi^2$  test)

	G135C polymorphism						<i>P</i>
	CC		GG		GC		
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%	
Stage							
I	0	0	10	71.4	4	28.6	0.232
II	0	0	14	82.4	3	17.6	
III	0	0	106	84.8	19	15.2	
IV	2	2.2	80	89.9	8	8.9	
Total	2		210		34		



**Fig. 2** Overall survival by Kaplan–Meier curves and Breslow test of NSCLC patients according to *RAD51* G135C genotypes



**Fig. 3** Overall survival by Kaplan–Meier curves and Breslow test of NSCLC patients according to *RAD51* genotypes and smoking history. **a** Smoker and ex-smoker NSCLC patients. **b** Non-smoker patients

extensive preclinical and clinical research, the overall prognosis for patients with NSCLC remains poor, with a 5-year survival rate of only 14% [36].

Individual characteristics, such as genetic variations, are believed to be associated with an altered response to a chemotherapeutic treatment. Therefore, as predictive factors, it becomes important to study and understand the role of polymorphisms in cancer susceptibility and also in treatment response [27, 37].

The *RAD51* gene is essential for survival in the absence of exogenous DNA damaging agents [39] and has a key role in the homologous recombination and repair of DNA [33]. Overexpression of human RAD51 protein has been observed in tumour cell lines of widely different origins [31] and increased levels of the protein have been correlated with elevated recombination rates [23]. It is also required for resistance to ionizing radiation [5, 28], and high levels of RAD51 have been correlated with resistance to chemotherapeutic agents [12, 35]. According to previous studies in other tumour models, the study of *RAD51* gene seems to be important for the prediction of treatment response with chemotherapeutic drugs [6].

Previous studies suggest that the aberrant overexpression of RAD51 protein could confer several advantages to tumour cells. First, the DNA repair function of *RAD51* may protect cells from DNA damage and apoptosis. Second, overstimulation of homologous recombination and chromatid exchange mechanisms by RAD51 protein may contribute to genomic instability and genetic diversity of tumour cells [31]. The increased RAD51 protein expression leads to a perturbation of the cellular state of equilibrium, reflected in alterations of gene expression patterns detectable at the mRNA level [29].

There has been, however, little comprehensive examination of DNA repair processes, which might significantly contribute to the removal of therapeutic drugs, such as cisplatin, 5-FU and taxol and/or irradiation-induced DNA damage. In general, RAD51 expression seems to be correlated with resistance to therapeutic drugs [40]. Thus, a basal level of *RAD51* appears to be required for the processing of spontaneous DNA lesions. The constitutive overproduction of RAD51 in human tumours [25, 26] and in some transformed cell lines [31] may contribute for cytotoxic drug resistance induced by RAD51 in human cancers [14].

There are some studies that investigated the role of this polymorphism in the genetic susceptibility for development breast cancer [7, 16, 17, 20, 24], gastric cancer [30] and acute myeloid leukaemia [32, 42]. However, to the best of our knowledge, this is the first study evaluating the effect of the *RAD51* G135C polymorphism in NSCLC patient survival.

Our results suggest that the *RAD51* G135C 5'-UTR genotypes may provide additional prognostic information in NSCLC patients who underwent first line-based



chemotherapy. In this study, our results demonstrate that the G135C C-allele is associated with a higher survival time, conferring a better prognosis than the GG genotype carrier patients (56.0 months vs. 41.7 months;  $p = 0.024$ ). Thus, individuals carrying the C allele showed an overall survival of approximately 56 months after chemotherapy, compared with 42 months for individuals carrying the allele G.

This study also indicates that the influence of *RAD51* G135C polymorphism in treatment response of NSCLC patients seems to be modulated by smoking history. Our results demonstrate that smoker or ex-smoker patients carriers of *RAD51* C-allele present a higher mean overall survival time, of 56 months comparing with 45 months for patients with GG genotype ( $p = 0.034$ ). However, this association was not observed in non-smoker patients ( $p = 0.413$ ).

*RAD51* expression was identified as an independent predictor for tumour recurrence, as well as for tumour progression. These data demonstrate *RAD51* expression as a clinically significant prognostic marker. Increased *RAD51* protein levels could lead to uncontrolled recombination, genome instability, prevention of apoptosis, cell cycle arrest and increased resistance of tumours to radiotherapy and chemotherapy. As down-regulation of *RAD51* protein by anti-sense oligonucleotides or small molecules sensitizes cells to DNA-damaging agents [28], this may be a promising strategy for tumour therapy [14].

Polymorphisms in untranslated regions have been shown to be important for cell proliferation, differentiation, tumour suppression, and metastasis suppression on several genes [9, 10]. For this reason, *RAD51* G135C polymorphism at the 5' UTR region can have an important role on protein expression and stability. As it is located in the 5'-untranslated region of the *RAD51* gene, this genetic variation could affect mRNA stability and/or translation efficiency, leading to altered product levels, which could alter the function of *RAD51* protein [3]. Although some known regulatory elements are associated with 5'-UTRs [11], it is not clear how 135C polymorphism might affect gene function. Hasselbach et al. [13] suggested promoter activity enhancement by substituting G at the polymorphic position +135, so that the C-allele is associated with lower *RAD51* expression levels.

Since increased *RAD51* protein levels could lead to uncontrolled recombination, genome instability and increased tumour resistance to chemotherapy, we hypothesize that the C-allele of *RAD51* polymorphism could derive lower protein expression levels, originating sensitized tumour cells, susceptible to chemotherapy treatment.

Thus, the presence of the G135C polymorphism may have a positive influence in treatment response, decreasing *RAD51* expression levels in tumour cells and originating sensitized tumour cells, with normal cell proliferation, competent for apoptosis, with reduced recombination and presenting chemotherapy sensitivity.

To the best of our knowledge, this was the first study evaluating potential prognostic and predictive role of *RAD51* G135C polymorphism in NSCLC patients treated with combined platinum taxanes/gemcitabine first line chemotherapy.

We believe that *RAD51* genotypes could be useful molecular markers for predicting the clinical outcome of NSCLC patients. Furthermore, in the attempt of optimizing responses, minimizing toxicities, and reducing the elevated costs associated with chemotherapy failure, the analysis of a wide range of molecular markers and genetic polymorphisms may contribute to the development of a pharmacogenomic profile, indicating the more appropriate chemotherapeutic protocol for each individual patient.

**Acknowledgments** The authors thank the Liga Portuguesa Contra o Cancro (Portuguese League against Cancer) – Centro Regional do Norte for their support. We also gratefully acknowledge for financial support of individual grant for Doctoral degree of the second author to Minister of Science, Technology and Superior Education-FCT (Fundação para a Ciência e Tecnologia: SFRH/BD/29898/2006).

**Conflict of interest statement** None.

## References

- Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. *Chest* 123:21S–49S
- Arnaudeau C, Lundin C, Helleday T (2001) DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. *J Mol Biol* 307:1235–1245
- Blasiak J, Przybylowska K, Czechowska A, Zadrozny M, Pertynski T, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J (2003) Analysis of the G/C polymorphism in the 5'-untranslated region of the *RAD51* gene in breast cancer. *Acta Biochim Pol* 50:249–253
- Cohen V, Khuri FR (2004) Chemoprevention of lung cancer. *Curr Opin Pulm Med* 10:279–283
- Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP (2001) Ribozyme minigene-mediated *RAD51* down-regulation increases radiosensitivity of human prostate cancer cells. *Nucleic Acids Res* 29:1534–1538
- Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW (2006) Pilot study examining tumor expression of *RAD51* and clinical outcomes in human head cancers. *Int J Oncol* 28:1113–1119
- Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. *Breast Cancer Res Treat* 103:209–217
- Daboussi F, Dumay A, Delacote F, Lopez BS (2002) DNA double-strand break repair signalling: the case of *RAD51* post-translational regulation. *Cell Signal* 14:969–975
- Facher EA, Becich MJ, Dekka A, Law JC (1997) Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. *Cancer* 79:2424–2429
- Fan H, Villegas C, Huang A, Wright JA (1996) Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. *Cancer Res* 56:4366–4369

11. Gray NK, Wickens M (1998) Control of translation initiation in animals. *Annu Rev Cell Dev Biol* 14:399–458
12. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T (2003) The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. *Int J Cancer* 105:472–479
13. Hasselbach L, Haase S, Fischer D, Kolberg HC, Sturzbecher HW (2005) Characterisation of the promoter region of the human DNA-repair gene Rad51. *Eur J Gynaecol Oncol* 26:589–598
14. Henning W, Sturzbecher HW (2003) Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. *Toxicology* 193:91–109
15. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. *Lancet* 355:479–485
16. Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, Adler L, Lubinski J, Scott RJ, Hamann U (2007) The RAD51 135 G > C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. *Cancer Epidemiol Biomarkers Prev* 16:270–275
17. Jara L, Acevedo ML, Blanco R, Castro VG, Bravo T, Gomez F, Waugh E, Peralta O, Cabrera E, Reyes JM, Ampuero S, Gonzalez-Hormazabal P (2007) RAD51 135G > C polymorphism and risk of familial breast cancer in a South American population. *Cancer Genet Cytogenet* 178:65–69
18. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. *CA Cancer J Clin* 55:10–30
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. *CA Cancer J Clin* 57:43–66
20. Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T (2004) A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or non-carriers. *Br J Cancer* 90:2002–2005
21. Karran P (2000) DNA double strand break repair in mammalian cells. *Curr Opin Genet Dev* 10:144–150
22. Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. *Nat Genet* 27:247–254
23. Lambert S, Lopez BS (2000) Characterization of mammalian RAD51 double strand break repair using non-lethal dominant-negative forms. *EMBO J* 19:3090–3099
24. Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. *Proc Natl Acad Sci USA* 98:3232–3236
25. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttes J, Kalthoff H, Sturzbecher HW (2000) DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. *Oncogene* 19:2791–2795
26. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, Feller AC, Lopens A, Diedrich K, Schwinger E, Sturzbecher HW (2000) Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. *Int J Cancer* 88:907–913
27. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T, Lopes C (2003) Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. *Int J Clin Oncol* 8:156–161
28. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T (1998) In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. *Biochem Biophys Res Commun* 245:319–324
29. Orre LM, Falt S, Szeles A, Lewensohn R, Wennborg A, Flygare J (2006) Rad51-related changes in global gene expression. *Biochem Biophys Res Commun* 341:334–342
30. Poplawski T, Arabski M, Kozirowska D, Blasinska-Morawiec M, Morawiec Z, Morawiec-Bajda A, Klupinska G, Jeziorski A, Chojnacki J, Blasiak J (2006) DNA damage and repair in gastric cancer—a correlation with the hOGG1 and RAD51 genes polymorphisms. *Mutat Res* 601:83–91
31. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T (2002) Elevated levels of Rad51 recombination protein in tumor cells. *Cancer Res* 62:219–225
32. Rollinson S, Smith AG, Allan JM, Adamson PJ, Scott K, Skibola CF, Smith MT, Morgan GJ (2007) RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia. *Leuk Res* 31:169–174
33. Schmutte C, Tomblin G, Rhiem K, Sadoff MM, Schmutzler R, von Deimling A, Fishel R (1999) Characterization of the human Rad51 genomic locus and examination of tumors with 15q14–15 loss of heterozygosity (LOH). *Cancer Res* 59:4564–4569
34. Shinohara A, Ogawa H, Matsuda Y, Ushio N, Ikeo K, Ogawa T (1993) Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA. *Nat Genet* 4:239–243
35. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T (2002) Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. *Mol Cell Biol* 22:4189–4201
36. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. *N Engl J Med* 350:379–392
37. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiani G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. *Oncogene* 23:3328–3337
38. Takahashi E, Matsuda Y, Hori T, Yasuda N, Tsuji S, Mori M, Yoshimura Y, Yamamoto A, Morita T, Matsushiro A (1994) Chromosome mapping of the human (RECA) and mouse (Reca) homologs of the yeast RAD51 and *Escherichia coli* recA genes to human (15q15.1) and mouse (2F1) chromosomes by direct R-banding fluorescence in situ hybridization. *Genomics* 19:376–378
39. Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M, Matsushiro A, Yoshimura Y, Morita T (1996) Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. *Proc Natl Acad Sci USA* 93:6236–6240
40. Vispe S, Cazaux C, Lesca C, Defais M (1998) Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. *Nucleic Acids Res* 26:2859–2864
41. Vispe S, Defais M (1997) Mammalian Rad51 protein: a RecA homologue with pleiotropic functions. *Biochimie* 79:587–592
42. Voso MT, Fabiani E, D'Alo F, Guidi F, Di Ruscio A, Sica S, Pagano L, Greco M, Hohaus S, Leone G (2007) Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. *Ann Oncol* 18:1523–1528
43. Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hummerich J, Muller DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A (1996) Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. *Oncogene* 12:973–978
44. Yamamoto A, Taki T, Yagi H, Habu T, Yoshida K, Yoshimura Y, Yamamoto K, Matsushiro A, Nishimune Y, Morita T (1996) Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. *Mol Gen Genet* 251:1–12
45. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, Gardner HD, Sullivan R, Gamble GD (2009) Lung cancer susceptibility model based on age, family history and genetic variants. *PLoS ONE* 4:e5302
46. Yuan SS, Chang HL, Lee EY (2003) Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM(−/−) and c-Abl(−/−) cells. *Mutat Res* 525:85–92